Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

In this study, the authors estimated that Paxlovid reduced the risk of hospitalization by 39% (95% confidence interval [CI], ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Moderna's strategy in 2025 focuses on maintaining its COVID-19 immunization market share while advancing its late-stage candidate pipeline. Within respiratory vaccines, the company anticipates FDA ...